Nanatinostat (CHR-3996) TFA is a potent, class I selective and orally active HDAC inhibitor with IC 50 s of 3 nM, 4 nM, and 7 nM for HDAC1 , HDAC2 , and HDAC3 , respectively. Nanatinostat TFA has low activity against HDAC5 (IC 50 of 200 nM) and HDAC6 (IC 50 of 2100 nM). Nanatinostat TFA induces apoptosis in myeloma cells. Nanatinostat TFA has potent anticancer effects, such as myeloma, advanced solid tumours and colorectal cancer .
Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > HDAC | Products > Signaling Pathways > Apoptosis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.